We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

4 hedge funds and large institutions have $1.31M invested in XTL Biopharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $1.23M → $1.31M (+$89K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.2% less ownership

Funds ownership: 4.38% → 4.18% (-0.2%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$644

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$41.9K
2
Citadel Advisors
Citadel Advisors
Florida
-$17K
3
TRCT
Tower Research Capital (TRC)
New York
-$215

XTLB Hedge Fund Activity: Q2 2016 in Review

4 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2016, worth a combined $1.31M — up 7.3% from $1.23M a quarter earlier.

Fund positioning in XTLB was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $644. The largest seller was Sabby Management, cutting an estimated $41.9K.

  • 4 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $1.31M of XTL Biopharmaceuticals stock for Q2 2016, up 7.3% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q2 2016 and 1 closed out, a net change of 0 holders.
  • The largest XTL Biopharmaceuticals buyer in Q2 2016 was Morgan Stanley, an estimated $644 added.
  • The largest XTL Biopharmaceuticals seller in Q2 2016 was Sabby Management, an estimated $41.9K sold.

Based on aggregated 13F filings for Q2 2016.